The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
Open accessAbstract
In this marker evaluation study, we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways and DNA repair that predict clinical outcome to 5-fluorouracil (5-FU)/oxaliplatin chemotherapy in patients with advanced colorectal cancer could be identified. Functional polymorphisms in DNA-repair genes XPD, ERCC1, XRCC1, XPA, and metabolising genes glutathione S-transferase GSTP1, GSTT1, GSTM1, and thymidylate synthase (TS) were assessed retrospectively in 106 patients with refractory stage IV disease who received 5-FU/oxaliplatin combination chemotherapy, using a polymerase chain reaction-based RFLP technique. Favourable genotypes from polymorphisms in XPD-751, ERCC1-118, GSTP1-105, and TS-3'-untranslated region (3'UTR) that are associated with overall survival were identified. After adjustment for performance status, the relative risks of dying for patients who possessed the unfavourable genotype were: 3.33 for XPD-751 (P=0.037), 3.25 for GSTP1-105 (P=0.072), 2.05 for ERCC1-118 (P=0.037), and 1.65 for TS-3'UTR (P=0.091) when compared to their respective beneficial genomic variants. Combination analysis with all four polymorphisms revealed that patients possessing > or =2 favourable genotypes survived a median of 17.4 months (95% confidence interval (CI): 9.4, 26.5) compared to 5.4 months (95% CI: 4.3, 6.0) in patients with no favourable genotype. Patients who carried one favourable genotype demonstrated intermediate survival of 10.2 months (95% CI: 6.8, 15.3; P<0.001). Polymorphisms in the TS-3'UTR and GSTP1-105 gene were also associated with time to progression. After adjustment for performance status, patients with an unfavourable TS-3'UTR genotype had a relative risk of disease progression of 1.76 (P=0.020) and those with the unfavourable GSTP1-105 genotype showed a relative risk of progression of 2.00 (P=0.018). The genomic polymorphisms XPD-751, ERCC1-118, GSTP1-105, and TS-3'UTR may be useful in predicting overall survival and time to progression of colorectal cancer in patients who receive 5-FU/oxaliplatin chemotherapy. These findings require independent prospective confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Miller, R. G. (1981) · Cited by 3,336
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“This would be especially useful now that we are at a juncture where equivalent chemotherapeutic regimens with differing mechanisms of action are available for the treatment of advanced colorectal cancer (Tournigand et al, 2004).”
BackgroundPharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Mehta, C. R., & Patel, N. R. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477989 · Cited by 898
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Harries, L. (1997) · Carcinogenesis · doi:10.1093/carcin/18.4.641 · Cited by 737
Johnston, P. G., Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., & Leichman, L. (1995) · PubMed · Cited by 672
Self-citationWatson, M. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.275 · Cited by 668
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Self-citationThymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V, Xiong, Y.-P., Ingles, S. A., Sherrod, A., Warren, R., Tsao-Wei, D., Groshen, S., & Lenz, H.-J. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500012 · Cited by 571
Self-citationHorie, N., Aiba, H., Oguro, K., Hojo, H., & Takeishi, K. (1995) · Cell Structure and Function · doi:10.1247/csf.20.191 · Cited by 547
A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables
Mehta, C. R., & Patel, N. R. (1983) · Journal of the American Statistical Association · doi:10.2307/2288652 · Cited by 538
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505
Self-citationModulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.
Spitz, M. R., Wu, X., Wang, Y., Wang, L.-E., Shete, S. S., Amos, C. I., Guo, Z., Lei, L., Mohrenweiser, H. W., & Wei, Q. (2001) · PubMed · Cited by 489
London, S. J., Yuan, J.-M., Chung, F.-L., Gao, Y.-T., Coetzee, G. A., Ross, R. K., & Yu, M. C. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02631-3 · Cited by 436
XPD polymorphisms: effects on DNA repair proficiency
Lunn, R. M., Helzlsouer, K. J., Parshad, R., Umbach, D. M., Harris, E. L., Sanford, K. K., & Bell, D. A. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.551 · Cited by 431
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Stoehlmacher, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.936 · Cited by 384
Self-citationGebhardt, F., Zänker, K. S., & Brandt, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13176 · Cited by 372
Mandola, M. V., Stoehlmacher, J., Muller‐Weeks, S., Cesarone, G., Yu, M. C., Lenz, H., & Ladner, R. D. (2003) · PubMed · Cited by 362
Self-citationArand, M., Mühlbauer, R., Hengstler, J., Jäger, E., Fuchs, J., Winkler, L., & Oesch, F. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0153 · Cited by 335
Human xeroderma pigmentosum group D gene encodes a DMA helicase
Sung, P., Bailly, V., Weber, C., Thompson, L. H., Prakash, L., & Prakash, S. (1993) · Nature · doi:10.1038/365852a0 · Cited by 311
Bootstrap investigation of the stability of a cox regression model
Altman, D. G., & Andersen, P. K. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080702 · Cited by 310
Villafranca, E., Okruzhnov, Y., Dominguez, M. A., García-Foncillas, J., Azinovic, I., Martínez, E., Illarramendi, J. J., Arias, F., Martínez-Monge, R., Salgado, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1779 · Cited by 308
1989 American Association for Cancer Research
Schwartz, E. L. (1989) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00393344 · Cited by 295
Kawakami, K., Omura, K., Kanehira, E., & Watanabe, Y. (1999) · PubMed · Cited by 282
Ulrich, C. M., Bigler, J., Velicer, C. M., Greene, E. A., Farin, F. M., & Potter, J. D. (2000) · PubMed · Cited by 259
Kawakami, K., Salonga, D. S., Park, J. M., Danenberg, K. D., Uetake, H., Brabender, J., Omura, K., Watanabe, G., & Danenberg, P. V. (2001) · PubMed · Cited by 258
LIMA, J., THOMASON, D., MOHAMED, M., EBERLE, L., SELF, T., & JOHNSON, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70071-8 · Cited by 250
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
Marsh, S., McKay, J., Cassidy, J., & McLeod, H. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.383 · Cited by 205
Chen, C., & George, S. L. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040107 · Cited by 202
Yu, J. J., Lee, K. B., Mu, C., Li, Q., Abernathy, T. V., Bostick-Bruton, F., & Reed, E. (2000) · International Journal of Oncology · doi:10.3892/ijo.16.3.555 · Cited by 200
Goto, S., Iida, T., Cho, S., Oka, M., Kohno, S., & Kondo, T. (1999) · Free Radical Research · doi:10.1080/10715769900301121 · Cited by 187
Dybdahl, M., Vogel, U. B., FRENTZ, G., Wallin, H., & Nexø, B. A. (1999) · PubMed · Cited by 186
Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., & Niitsu, Y. (1996) · PubMed · Cited by 183
Etienne, M.-C., Chazal, M., Laurent-Puig, P., Magné, N., Rosty, C., Formento, J.-L., Francoual, M., Formento, P., Renée, N., Chamorey, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.091 · Cited by 176
Stoehlmacher, J., Ghaderi, V., Iobal, S., Groshen, S. G., Tsao-Wei, D. D., Park, D., & Lenz, H. (2001) · PubMed · Cited by 172
Self-citationAschele, C., Lonardi, S., & Monfardini, S. (2002) · Cancer Treatment Reviews · doi:10.1053/ctrv.2002.0253 · Cited by 96
Qing, G., Liu, C. H., Ben-Av, P., & Hla, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7994 · Cited by 81
Rajagopalan, L. E., & Malter, J. S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740052.x · Cited by 24
Cited by
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Genetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Van Cutsem, E., Nordlinger, B., Adam, R., Köhne, C.-H., Pozzo, C., Poston, G., Ychou, M., & Rougier, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.012 · Cited by 587
Performance guarantees for individualized treatment rules
Qian, M., & Murphy, S. A. (2011) · The Annals of Statistics · doi:10.1214/10-aos864 · Cited by 444
3′ end mRNA processing: molecular mechanisms and implications for health and disease
Danckwardt, S., Hentze, M. W., & Kulozik, A. E. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601932 · Cited by 296
Metadata
- Authors
- Stoehlmacher, J., Park, D. J., Zhang, W., Yang, D., Groshen, S., Zahedy, S., & Lenz, H.-J.
- Venue
- British Journal of Cancer
- Published
- 2004-06-22
- Volume
- 91
- Issue
- 2
- Pages
- 344-354
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2065829703
- Cited by
- 364
- References
- 45
- FWCI
- 16.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.